Category: 74904-29-3

On November 30, 2013, Abate, Carmen; Selivanova, Svetlana V.; Muller, Adrienne; Kramer, Stefanie D.; Schibli, Roger; Marottoli, Roberta; Perrone, Roberto; Berardi, Francesco; Niso, Mauro; Ametamey, Simon M. published an article.Related Products of 74904-29-3 The title of the article was Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors. And the article contained the following:

σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their d. With the aim of contributing to the research of σ2 receptor Positron Emission Tomog. (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3,4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacol. properties and appropriate lipophilicity. Hence, 3 served as the lead compound for the development of a series of dihydroisoquinolinones amenable to radiolabeling. Radiosynthesis for compound 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiog. on rat brain slices. Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp. Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to brain, homo sapiens, human, positron emission tomography, tomography imaging agents, tumor imaging, σ1-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study), σ2-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study) and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 18, 1982, Kashdan, David S.; Schwartz, John A.; Rapoport, Henry published an article.Category: isoquinoline The title of the article was Synthesis of 1,2,3,4-tetrahydroisoquinolines. And the article contained the following:

Several aspects of 1,2,3,4-tetrahydroisoquinoline synthesis were examined An improved synthesis of 2-(m-methoxyphenyl)ethylamine (I) is reported. m-Anisaldehyde was treated with KCN and EtO2CCl to yield O-(ethoxycarbonyl)-3-methoxymandelonitrile. Hydrogenation gave I in 87% yield overall. Some observations were made regarding the reduction of 3,4-dihydroisoquinolines derived from the Bischler-Napieralski reaction. Amides II (R = R1 = MeO; R = H, R1 = OCH2Ph) were cyclized with POCl3 followed by reduction to the corresponding tetrahydroisoquinolines III, which were contaminated with 4% of IV (R = R1 = MeO) and 3% of IV (R = H, R1 = OCH2Ph), resp. Both IV (R = R1 = OMe) and IV (R = H, R1 = OCH2Ph) were independently synthesized by routes with general applicability to 8-alkoxy-1,2,3,4-tetrahydroisoquinolines. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Category: isoquinoline

The Article related to tetrahydroisoquinoline, hydroisoquinoline tetra, isoquinoline tetrahydro, phenethylbenzeneacetamide bischler napieralski cyclization, acetamide phenethylbenzene cyclization and other aspects.Category: isoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 29, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.; Chao, Jianhua; Yu, Younong; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert; Biju, Purakkattle J.; Nelson, Kingsley H.; Rokosz, Laura L.; Jakway, James P.; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Application of 74904-29-3 The title of the patent was Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Title compounds [I; A = (substituted) pyridylmethyl, thiazolylmethyl, benzofurylmethyl, isoxazolylmethyl, pyrazinylmethyl, triazolylmethyl, phenylalkyl, etc.; B = (substituted) Ph, benzotriazolyl, benzimidazolyl, imidazolyl, pyrazolyl, hydroxypyridinyl, thienyl, pyrrolyl, isothiazolyl, etc.], were prepared Thus, title compound (II) (preparation outlined) showed Ki = 0.8 nM in a CXCR2 SPA receptor binding assay. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Application of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, cyclobutenedione diamino preparation cxc chemokine receptor ligand, squaric acid amide preparation cancer pain inflammation contusion treatment and other aspects.Application of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 5, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Chao, Jianping; Dwyer, Michael; Chao, Jianhua; Yu, Younong; Merritt, J. Robert; Biju, Purakkattle; Jakway, James; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Product Details of 74904-29-3 The title of the patent was Preparation of 3,4-di(substituted amino)cyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds of the formula (I) or pharmaceutically acceptable salts or solvates thereof [A = Q, Q1; B = substituted Ph, (un)substituted 1H-pyrazol-3-yl, 1H-pyrazol-5-yl, 2- or 3-thienyl, 1H-pyrrol-3-yl, 1H-pyrrol-2-yl, isothiazol-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-3-yl, 4-hydroxypyrimidin-4-yl, or 4-hydroxypyridin-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-5-yl, 1,4-dihydro-1-hydroxy-4-oxopyridin-2-yl, 1H-benzotriazol-7-yl, 1H-benzimidazol-7-yl, 1H-indol-7-yl, or benzo[c]pyrazol-7-yl; R7, R8 = H, each (un)substituted alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, CO2H, CONH2, alkynyl, alkenyl, cycloalkenyl; R12 = H,each (un)substituted CO2H, aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl, or heteroarylalkyl group]. Also disclosed is the treatment of chemokine-mediated diseases, where the chemokine binds to CXCR2 and/or CXCR1 receptor, using compounds of the formula I. The diseases include chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, chronic neuropathic pain, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, septic shock, endotoxic shock, gram neg. sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer’s disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral and cardiac ischemia, osteoarthritis, multiple sclerosis, restenosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi’s sarcoma associated virus, meningitis, cystic fibrosis, preterm labor, cough, pruritis, multiorgan dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, and subarachnoid hemorrhage. They also include post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alc. hepatitis, necrotizing enterocolitis, chronic sinusitis, angiogenic ocular disease, ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, cough, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alc. liver disease, lupus, burn therapy, periodontitis, transplant reperfusion injury and early transplantation rejection, acute inflammation, and rheumatoid arthritis as well as cancer. The compounds I had IC50 of <10 μM for inhibiting the binding of [125I]-IL-8 to human chemokine receptor CXCR1. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Product Details of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, inflammation treatment aminocyclobutenedione preparation, inflammatory pain treatment aminocyclobutenedione preparation, cancer treatment aminocyclobutenedione preparation, psoriasis treatment aminocyclobutenedione preparation, atopic dermatitis treatment aminocyclobutenedione preparation and other aspects.Product Details of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem